1. Clinical effectiveness of four neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, and peramivir) for children with influenza A and B in the 2014-2015 to 2016-2017 influenza seasons in Japan
- Author
-
Ishiguro, Nobuhisa, Koseki, Naoko, Kaiho, Miki, Ariga, Tadashi, Kikuta, Hideaki, Oba, Koji, Togashi, Takehiro, Morita, Keisuke, Inagawa, Akira, Okamura, Akiko, Yamazaki, Shigeru, Shida, Satoru, Konno, Mutsuko, Kawamura, Nobuaki, Ishizaka, Akihito, Takada, Kimihiko, Tsubakihara, Keiji, Nagano, Naoko, Shibata, Mutsuo, Furuyama, Hideto, Matsuzono, Yoshihiro, Koike, Akemi, Murashita, Mari, Hatae, Yoshio, Arioka, Hideki, Yamanaka, Tatsuru, Watanabe, Toru, Tabata, Yuuichi, Kumita, Yoshihiro, Hazama, Kyosuke, Akutsu, Yasushi, Aoyagi, Hayato, Tobise, Chie, Azuma, Katsuki, Yasoshima, Kohichi, Sawada, Yoko, Uetsuji, Kazuyuki, Tsuchida, Akira, Tsuchiyama, Akira, Yasuda, Kazue, Odagawa, Yasuhisa, Yoshioka, Mikio, Ishiguro, Nobuhisa, Koseki, Naoko, Kaiho, Miki, Ariga, Tadashi, Kikuta, Hideaki, Oba, Koji, Togashi, Takehiro, Morita, Keisuke, Inagawa, Akira, Okamura, Akiko, Yamazaki, Shigeru, Shida, Satoru, Konno, Mutsuko, Kawamura, Nobuaki, Ishizaka, Akihito, Takada, Kimihiko, Tsubakihara, Keiji, Nagano, Naoko, Shibata, Mutsuo, Furuyama, Hideto, Matsuzono, Yoshihiro, Koike, Akemi, Murashita, Mari, Hatae, Yoshio, Arioka, Hideki, Yamanaka, Tatsuru, Watanabe, Toru, Tabata, Yuuichi, Kumita, Yoshihiro, Hazama, Kyosuke, Akutsu, Yasushi, Aoyagi, Hayato, Tobise, Chie, Azuma, Katsuki, Yasoshima, Kohichi, Sawada, Yoko, Uetsuji, Kazuyuki, Tsuchida, Akira, Tsuchiyama, Akira, Yasuda, Kazue, Odagawa, Yasuhisa, and Yoshioka, Mikio
- Abstract
The clinical effectiveness of four neuraminidase inhibitors (NAIs) (oseltamivir, zanamivir, laninamivir, and peramivir) for children aged 0 months to 18 years with influenza A and B were investigated in the 2014-2015 to 2016-2017 influenza seasons in Japan. A total of 1207 patients (747 with influenza A and 460 with influenza B) were enrolled. The Cox proportional-hazards model using all of the patients showed that the duration of fever after administration of the first dose of the NAI was shorter in older patients (hazard ratio = 1.06 per 1 year of age, p < 0.001) and that the duration of fever after administration of the first dose of the NAI was shorter in patients with influenza A infection than in patients with influenza B infection (hazard ratio = 2.21, p < 0.001). A logistic regression model showed that the number of biphasic fever episodes was 2.99-times greater for influenza B-infected patients than for influenza A-infected patients (p < 0.001). The number of biphasic fever episodes in influenza A-or B-infected patients aged 0-4 years was 2.89-times greater than that in patients aged 10-18 years (p = 0.010), and the number of episodes in influenza A-or B-infected patients aged 5-9 years was 2.13times greater than that in patients aged 10-18 years (p = 0.012).
- Published
- 2018